Undisclosed ApoA1-Anti CD99 antibody fusion protein / NanoValent Pharma - LARVOL DELTA

Enhanced therapeutic efficacy of ApoA1-Anti CD99 antibody fusion protein for treatment of Ewing sarcoma (AACR 2026) - "Much better tumor reduction has been observed at doses as low as 0.5 mg/kg irinotecan, treated twice per week, which was superior to 1 mg/kg NV103 treated biweekly. In conclusion, HPLN/Ir formulated with anti-CD99 antibodies fused with ApoA1 demonstrated substantially greater efficacy against Ewing Sarcoma. We anticipate that this approach will enhance tumor cell binding and drug targeting broadly for other antibodies and nanoparticle formulations."

Clinical • Late-breaking abstract • Ewing Sarcoma • Oncology • Sarcoma • Solid Tumor • APOA1 • CD99